Cory Kasimov

Analysts Raise Price Targets On GW Pharma's Positive Earnings, Epidiolex Results

Juno Therapeutics Price Target Cut From $63 To $39 At JPMorgan

Clovis Investors Lose Roci Value Entirely, JPMorgan Sees Clovis Worth Just What Ruca Can Pay: $15/Share

Juno Therapeutics Price Target Cut From $63 To $39 At JPMorgan

Clovis Investors Lose Roci Value Entirely, JPMorgan Sees Clovis Worth Just What Ruca Can Pay: $15/Share

Puma Biotechnology Analysts Are Getting Nervous, But Still Going Long

JP Morgan Upgrades Celgene, Says 'Too Cheap To Ignore'

Puma Biotechnology Analysts Are Getting Nervous, But Still Going Long

JP Morgan Upgrades Celgene, Says 'Too Cheap To Ignore'

Bluebird Bio's Positive LentiGlobin Data: Wall Street Responds

JP Morgan Downgrades MannKind; Jefferies Also Comments

Cory Kasimov Recent News

Is Keryx Still A Good Buy After Weak Prescription Data?

Analysts Respond To Pharmacyclics' Q4 Results

J.P. Morgan Is Watching This 'Curve Ball' At Gilead

Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C

Novavax, Inc. Jumps 7% Amid JP Morgan Initiation

J.P. Morgan Sees Sangamo Biosciences, Inc. As Attractive Investment Opportunity

UPDATE: J.P. Morgan Initiates Coverage On Sangamo Biosciences On Potentially Disruptive Future

UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia News

UPDATE: J.P. Morgan Reiterates on Keryx Biopharmaceuticals on Model Update After Positive NDD-CKD Data

UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting Better Entry Point

UPDATE: J.P. Morgan Initiates Coverage on Pharmacyclics on Ibrutinib Potential

UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

UPDATE: J.P. Morgan Initiates Keryx Biopharmaceuticals at Overweight on Increasing Comfort With Key Controversies

UPDATE: J.P. Morgan Downgrades Rigel Pharmaceuticals to Neutral Following AZN Decision

UPDATE: J.P. Morgan Raises PT on Aegerion Pharmaceuticals in Continuing Doc Rounds Series

JP Morgan Upgrades Orexigen Therapeutics to Overweight

Ariad Pharmaceuticals' New Drug Shows Promise, Says JP Morgan

J.P. Morgan Maintains Human Genome Sciences (HGSI) Overweight Rating